STUDY SEARCH RESULTS

1 study found for your search request:  3475-B61

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma...
Condition: Renal Cell Carcinoma
Minimum Age: 18 years, Maximum Age: 120 years
Gender: All
Study ID: NCT04704219
Status: Completed
Has Results




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site